Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 ...

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

Kite, a Gilead Company, has announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir—Gilead's ...